Repligen (NASDAQ:RGEN) Issues FY 2024 Earnings Guidance

Repligen (NASDAQ:RGEN) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 1.420-1.490 for the period, compared to the consensus EPS estimate of 1.460. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $635.6 million. Repligen also updated its FY24 guidance to $1.42-1.49 EPS.

Repligen Trading Up 0.4 %

NASDAQ RGEN traded up $0.74 during mid-day trading on Friday, reaching $167.05. 454,984 shares of the stock were exchanged, compared to its average volume of 538,521. Repligen has a 1-year low of $110.45 and a 1-year high of $211.13. The business’s fifty day simple moving average is $180.81 and its 200 day simple moving average is $174.09. The stock has a market capitalization of $9.33 billion, a PE ratio of 668.23, a PEG ratio of 5.44 and a beta of 1.03. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 6.35.

Repligen (NASDAQ:RGEN) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The firm had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. During the same quarter last year, the business posted $0.64 EPS. The firm’s revenue was down 17.1% compared to the same quarter last year. On average, research analysts anticipate that Repligen will post 1.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on RGEN shares. KeyCorp lifted their price target on shares of Repligen from $210.00 to $220.00 and gave the company an overweight rating in a report on Thursday, February 15th. JPMorgan Chase & Co. decreased their price target on shares of Repligen from $230.00 to $200.00 and set an overweight rating on the stock in a report on Thursday. Finally, Stifel Nicolaus lifted their price target on shares of Repligen from $165.00 to $207.00 and gave the company a buy rating in a report on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus target price of $197.75.

Insider Activity

In related news, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the sale, the director now owns 87,367 shares of the company’s stock, valued at approximately $16,892,409.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction on Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the sale, the vice president now owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the sale, the director now directly owns 87,367 shares in the company, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,597 shares of company stock valued at $5,039,532. Company insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.